Garzone Pamela 4

What Happened Pamela Garzone, a director of Cue Biopharma, Inc. (CUE), received a grant of 21,800 restricted stock units (RSUs) on July 9, 2026. The grant was reported on a Form 4 filed July 10, 2026. The reported acquisition price is $0.00 (award/compensation), so the filing shows $0 in cash paid at grant — this is a compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: July 9, 2026; Form 4 filed: July 10, 2026 (timely filing).
• Transaction type/code: Award/Grant (A).
• Shares granted: 21,800 RSUs; grant price reported as $0.00.
• Vesting: One-third of the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service (footnote F1).
• Shares owned after transaction: not specified in the provided filing details.
• No 10b5-1 plan, tax-withholding, or cashless-sale notes were reported in the provided information.

Context RSUs represent a promise to deliver shares if and when they vest; they are common as compensation for executives and directors. Because these shares vest over future dates and require continued service, this grant does not represent immediate share ownership or an open-market investment by the insider. Such awards are routine corporate compensation and should not be interpreted alone as a bullish or bearish signal.